The first bank of China fund to release its second Quarterly Report
As of 3 p.m. today, BOC fund disclosed the second quarterly report of nine products, including one flexible configuration product, two commodity based products and six debt based products. Among them, the net asset value of Bank of China Healthcare fund managed by Liu Xiao reached 1.264 billion yuan (A / C combined calculation) at the end of the second quarter, with a growth rate of 17.88% in the quarter. Compared with the previous quarter, Beida pharmaceutical, Aier ophthalmology and Lizhu group were newly added to the top ten heavy position stocks of the fund; And Yunnan Baiyao increased its position by 208500 shares, which is the largest position of the fund; Changchun hi tech, Zhifei biology, humanwell medicine, etc. withdrew from the top ten heavy position stocks. Fund managers said that their positions focused on innovative drugs, cro / cdmo and other industry leaders, and focused on the rise of domestic life technology industry supply chain.
This text is a result of machine translation.
Related companies：
Briefing Jun 20, 2022 04:54 PM
· Technology
The official results of the French parliamentary elections were announced, and the ruling party coalition held a relatively large number of seats
In-depth
Healthcare
Big Pharma CCHT’s Domination Unlikely to Fade Soon Despite Official Bulk Buying
The producer of long-acting growth hormone acupunctures, vaccines and other drugs, looks set to offset the effects of so-called “centralized procurement” on its product prices with more aggressive expansion into private hospitals. So far, its monopoly appears unshakable, but with more competitors upping the stakes, how long will it last?
Feb 21, 2022 02:30 PM
Briefing May 19, 2022 05:45 PM
· Healthcare
Shenzhen textile A: the order of line 7 is full, and the production line speed is climbing
Briefing May 18, 2022 04:45 PM
Taier shares: the contract dispute case against Cao Linbin was accepted by the court
Nov 16, 2022 05:19 PM
Nov 07, 2022 04:27 PM
Aug 29, 2022 05:45 PM
Apr 18, 2022 06:30 PM
Briefing Apr 27, 2022 05:16 PM
Beautiful Ecology: the net profit in the first quarter increased by 24.92% to 1.9755 million yuan
Healthcare
Yunnan Baiyao's Revenue Rises 33%; Net Profit Falls 40% in 1Q 2021
On April 27, Yunnan Baiyao released a report for the first quarter of 2021 showing that the company's total operating revenue for the first quarter was 10.33 billion yuan, up 33.4% year-on-year; its operating profit was 880 million yuan, down 41.8% year-on-year; its net profit attributable to shareholders of the listed company was 760 million yuan.
Apr 30, 2021 02:07 AM
Briefing Apr 25, 2022 06:25 PM
· Healthcare
Yingkang life: it is expected to lose 300 million yuan to 370 million yuan in 2021
In-depth
Healthcare
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Digital Zhengtong: new orders signed in the first two months increased by more than 60% year-on-year
Briefing Mar 15, 2022 12:19 PM
Half day main capital net inflow of power equipment, non bank finance, selling banks, etc
See more
Read next
Insight
In-depth
Consumer Discretionary · Analysis
Black Friday Kicks Off: How to Navigate the Latin American Market?
Nov 20, 2024 10:36 AM
Insight
In-depth
Consumer Staples, Consumer Discretionary · Interview
Exploring Uncharted Territories in the Middle East: The Innovators Going Global
Nov 19, 2024 03:20 PM
Insight
In-depth
Insight
In-depth
Consumer Staples
The Billion-Dollar European Caviar Business, Now Disrupted by China
Nov 08, 2024 01:52 PM